natgillin/translations-raw huggingface dataset:
The most frequently observed adverse drug reactions (ADRs) in patients receiving MabThera were infusion-related reactions which occurred in the majority of patients during the first infusion. 
Najpogosteje opaženi neželeni učinek pri prejemnikih zdravila MabThera so bile z infuzijo povezane reakcije, ki so se pri večini bolnikov pojavile med prvo infuzijo.
Specific studies to determine the effects of rituximab or rHuPH20 on fertility have not been performed. 
Specifičnih študij za ugotavljanje učinkov rituksimaba ali rHuPH20 na plodnost niso izvedli.
Patients should be instructed to contact their treating physician immediately if symptoms that are suggestive of severe hypersensitivity or cytokine release syndrome occur at any time after medicinal product administration. 
Bolnikom je treba naročiti, naj se nemudoma obrnejo na lečečega zdravnika, če se jim kadar koli po uporabi zdravila pojavijo simptomi, ki nakazujejo hudo preobčutljivost ali sindrom sproščanja citokinov.
In the clinical trial on induction of remission, which included 99 MabThera-treated patients, the overall rate of infection was approximately 237 per 100 patient years (95% CI 197 - 285) at the 6-month primary endpoint. 
V kliničnem preskušanju indukcije remisije, v katerega so vključili 99 bolnikov, zdravljenih z zdravilom MabThera, je bil celotni delež okužb na primarni končni točki po 6 mesecih približno 237 na 100 bolnik-let (95-% interval zaupanja, 197-285).
MabThera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. 
Vzdrževalno zdravljenje z zdravilom MabThera je indicirano za zdravljenje bolnikov s folikularnimi limfomi, ki se odzovejo na indukcijsko zdravljenje.
• general discomfort or feeling uneasy or tired, shaking, signs of flu 
· splošno nelagodje, neprijetno počutje ali utrujenost, tresenje, znaki gripe
Events of neutropenia were observed with MabThera treatment, the majority of which were transient and mild or moderate in severity. 
Nevtropenija Pri zdravljenju z zdravilom MabThera so opazili dogodke nevtropenije, ki so bili večinoma prehodni in po resnosti blagi ali zmerni.
The most commonly reported serious infection in the MabThera group was mild or moderate bronchitis. 
Najpogosteje zabeležena resna okužba v skupini bolnikov, ki so prejemali zdravilo MabThera, je bil blag ali zmeren bronhitis.
SPECIAL STORAGE CONDITIONS Store in a refrigerator (2 °C - 8 °C). 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte v hladilniku (2 °C do 8 °C).
It is important to check the medicinal product labels to ensure that the appropriate formulation (intravenous or subcutaneous formulation) and strength is being given to the patient, as prescribed. 
Pomembno je preveriti nalepke na zdravilu in tako zagotoviti, da bolnik dobi ustrezno obliko (intravensko ali podkožno) in jakost zdravila, ki mu je bila predpisana.
Geometric mean 
Geometrična sredina
Geometric mean AUC values at cycle 7 µg.day/mL 
AUC, vrednosti 7. cikel µg.dan/ml
At month 28, major relapse (defined by the reappearance of clinical and/or laboratory signs of vasculitis activity ([BVAS] > 0) that could lead to organ failure or damage or could be life threatening) occurred in 3 patients (5%) in the MabThera group and 17 patients (29%) in the azathioprine group (p=0.0007). 
Po 28 mesecih so hujši recidiv (opredeljen kot ponoven pojav kliničnih in/ali laboratorijskih znakov aktivnosti vaskulitisa ([BVAS] > 0), ki bi lahko povzročil odpoved organa ali okvaro ali bi lahko bil življenjsko nevaren) zabeležili pri 3 bolnikih (5 %) v skupini z zdravilom MabThera in pri 17 bolnikih
A total of 321 patients (162 R-CVP, 159 CVP) received therapy and were analysed for efficacy. 
Skupno so zdravili in glede učinkovitosti analizirali 321 bolnikov (162 R-CVP, 159 CVP).
• Information on the signs and symptoms of infections, especially PML, and the need to contact their doctor immediately if they experience any 
· podrobne podatke o tveganju za okužbe in PML, · informacije o znakih in simptomih okužb, še posebno PML, in informacije o nujnosti, da nemudoma obvestijo svojega zdravnika, če izkusijo katerega od znakov ali simptomov,
All of these arrhythmias either occurred in the context of a MabThera infusion or were associated with predisposing conditions such as fever, infection, acute myocardial infarction or pre-existing respiratory and cardiovascular disease. 
Vse motnje srčnega ritma so se pojavile v povezavi z infuzijo zdravila MabThera ali pa so bile povezane s predispozicijskimi stanji, kot so zvišana telesna temperatura, okužba, akutni miokardni infarkt ali predhodna respiratorna ali kardiovaskularna bolezen.
Results from other supportive studies using MabThera in combination with other chemotherapy regimens (including CHOP, FCM, PC, PCM, bendamustine and cladribine) for the treatment of previously untreated and/or relapsed/refractory CLL patients have also demonstrated high overall response rates with benefit in terms of PFS rates, albeit with modestly higher toxicity (especially myelotoxicity). 
Rezultati iz drugih podpornih študij z uporabo zdravila MabThera v kombinaciji z drugimi kemoterapijami (vključno s CHOP, FCM, PC, PCM, bendamustinom in kladribinom) za zdravljenje bolnikov s KLL, ki predhodno še niso bili zdravljeni in/ali pri katerih se je bolezen ponovila oziroma se na prejšnje zdravljenje niso odzvali, so prav tako pokazali visok delež celokupnih odgovorov s koristjo v smislu preživetja brez napredovanja bolezni, vendar z rahlo večjo toksičnostjo (predvsem mielotoksičnostjo).
The most frequently reported serious infection in the MabThera group was pneumonia at a frequency of 4%. 
Najpogosteje zabeležena okužba v skupini bolnikov, ki so prejemali zdravilo MabThera, je bila pljučnica; njena pogostnost je bila 4 %.
Significant difference from placebo + MTX at the primary timepoint: ***p ≤ 0.0001 
Značilna razlika v primerjavi s kombinacijo placebo + metotreksat ob času primarnega cilja preskušanja: ***p ≤ 0,0001
Data from the development programme of MabThera subcutaneous formulation indicate that the formation of anti-rituximab antibodies after subcutaneous administration is comparable with that observed after intravenous administration. 
Podatki iz razvojnega programa podkožne oblike zdravila MabThera kažejo, da je nastajanje protiteles proti rituksimabu po podkožni uporabi podobno, kot so ga opazili po intravenski uporabi.
Treatment with MabThera in combination with methotrexate over multiple courses resulted in sustained improvements in the clinical signs and symptoms of RA, as indicated by ACR, DAS28-ESR and EULAR responses which was evident in all patient populations studied (Figure 2). 
Zdravljenje z zdravilom MabThera v kombinaciji z metotreksatom v več ciklih je prineslo stalno izboljšanje kliničnih znakov in simptomov RA, kot so pokazali odzivi po ACR, DAS28-ESR in
• The importance of sharing this information with their partner or caregiver 
· pomembno dejstvo, da te informacije delijo s svojim partnerjem ali skrbnikom, · informacije o opozorilni kartici za bolnika.
Stage 1 enrolled previously untreated patients (n=127) CD20-positive, Follicular Lymphoma (FL) Grade 1, 2 or 3a. 
V 1. stopnjo so bili vključeni predhodno nezdravljeni bolniki (n = 127) s CD20-pozitivnimi folikularnimi limfomi gradusa 1, 2 ali 3a.
How much and how often you will receive your treatment a) If you are being treated for non-Hodgkin's Lymphoma 
Koliko zdravila boste dobili in kako pogosto a) Če se zdravite zaradi ne-Hodgkinovega limfoma · Če prejemate samo zdravilo MabThera,
Consultation with a Neurologist should be considered as clinically indicated. 
Posvet z nevrologom pride v poštev, kot je klinično ustrezno.
The information provided in the section 4.4 pertains to the use of MabThera subcutaneous formulation in the approved indications Treatment of non Hodgkin lymphoma (strength 1400 mg) and Treatment of CLL (strength 1600 mg). 
Informacije v poglavju 4.4 se nanašajo na uporabo podkožne oblike zdravila MabThera za odobreni indikaciji Zdravljenje ne-Hodgkinovega limfoma (jakost 1400 mg) in Zdravljenje kronične limfocitne levkemije (jakost 1600 mg).
The total number of cycles is of 6. 
Skupno zdravljenje obsega 6 ciklov.
d) If you are being treated for granulomatosis with polyangiitis or microscopic polyangiitis Treatment with MabThera uses four separate infusions given at weekly intervals. 
Če se zdravite zaradi granulomatoze s poliangiitisom ali mikroskopskega poliangiitisa Zdravljenje z zdravilom MabThera obsega štiri ločene infuzije, ki jih dobite v presledkih enega tedna.
The clinical relevance of the development of anti-rituximab antibodies or anti-rHuPH20 antibodies after treatment with MabThera subcutaneous formulation is not known. 
Klinični pomen pojava protiteles proti rituksimabu ali protiteles proti rHuPH20 po zdravljenju s podkožno obliko zdravila MabThera ni znan.
Should non-live vaccinations be required whilst receiving MabThera therapy, these should be completed at least 4 weeks prior to commencing the next course of MabThera. 
Če je potrebno cepljenje z mrtvimi cepivi med zdravljenjem z zdravilom MabThera, mora biti zaključeno najmanj 4 tedne pred začetkom naslednjega cikla zdravila MabThera.
Severe infusion-related reactions with fatal outcome have been reported during post-marketing use of the MabThera intravenous formulation, with an onset ranging within 30 minutes to 2 hours after starting the first MabThera intravenous infusion. 
Hude, z infuzijo povezane reakcije s smrtnim izidom, so bile opisane med obdobjem trženja z intravensko obliko zdravila MabThera; pojavile so se od 30 minut do 2 uri po začetku prve intravenske infuzije zdravila MabThera.
The majority of these patients were also exposed to cytotoxic chemotherapy. 
Večina teh bolnikov je hkrati prejemala tudi citotoksično kemoterapijo.
Patients who experience overdose or medication error should be closely monitored. 
Bolnike, pri katerih pride do prevelikega odmerjanja ali napake, povezane z zdravilom, je treba skrbno nadzorovati.
Maintenance infusions of MabThera 500 mg were administered at months 12 and 18. 
Vzdrževalni infuziji 500 mg zdravila MabThera sta bili uporabljeni 12. in 18. mesec.
Table 7: Trial BP22333 (SparkThera): Absorption - Pharmacokinetic parameters of MabThera SC compared to MabThera IV 
Preskušanje BP22333 (SparkThera): Absorpcija - farmakokinetični parametri zdravila MabThera podkožno v primerjavi z zdravilom MabThera intravensko MabThera podkožno
When you are treated with MabThera in combination with chemotherapy, you will receive a MabThera infusion on day 0 of cycle 1, then subcutaneous injections on day 1 of each subsequent cycle. 
Ko se boste zdravili z zdravilom MabThera v kombinaciji s kemoterapijo, boste dobili infuzijo zdravila MabThera 0. dan 1. cikla in nato podkožne injekcije 1. dan vsakega naslednjega cikla.
How it is given 
Kako se zdravilo daje
There was no impact of the presence of anti-rituximab or anti-rHuPH20 antibodies on safety, efficacy or PK of MabThera. 
Vpliva prisotnosti protiteles proti rituksimabu ali protiteles proti rHuPH20 na varnost, učinkovitost ali farmakokinetiko zdravila MabThera ni bilo.
A total of 334 patients achieving a complete or partial remission following induction therapy were randomised in a second step to MabThera maintenance therapy (n=167) or observation (n=167). 
334 bolnikov, ki so po indukcijskem zdravljenju dosegli popolni ali delni odgovor, randomiziranih v drugi del zdravljenja, v katerem so prejemali vzdrževalno zdravljenje z zdravilom MabThera (n = 167), ali v opazovano skupino (n = 167).
Adverse drug reactions presented in Table 5 were adverse events which occurred at a rate of ≥ 5% among MabThera-treated PV patients, with a ≥ 2% absolute difference in incidence between the MabThera-treated group and the standard-dose prednisone group up to month 24. 
V preglednici 5 prikazani neželeni učinki so tisti, ki so se med bolniki z navadnim pemfigusom, zdravljenimi z zdravilom MabThera, pojavili z ³ 5-odstotnim deležem, absolutna razlika v njihovi pojavnosti med skupino z zdravilom MabThera in skupino s standardnim odmerkom prednizona pa je bila do 24. meseca ³ 2 %.
Signs and symptoms suggestive of an infusion-related reaction were reported in more than 50% of patients in clinical trials, and were predominantly seen during the first infusion, usually in the first one to two hours. 
O znakih in simptomih, ki bi lahko nakazovali reakcije, povezane z infuzijo, so poročali pri več kot 50 % bolnikov v kliničnih preskušanjih; večinoma so jih opazili med prvo infuzijo, po navadi v prvih dveh urah.
In clinical trials with MabThera monotherapy given for 4 weeks, haematological abnormalities occurred in a minority of patients and were usually mild and reversible. 
V kliničnih preskušanjih z zdravilom MabThera kot samostojnim zdravilom, ki so ga bolniki prejemali 4 tedne, so se pri manjšem številu bolnikov pojavile hematološke nepravilnosti, ki pa so bile običajno blage in reverzibilne.
MabThera should be used in combination with CHOP chemotherapy. 
Zdravilo MabThera je treba uporabljati v kombinaciji s kemoterapijo CHOP.
• tumour pain 
· tumorske bolečine
A total of 392/3095 (12.7%) patients with rheumatoid arthritis tested positive for ADAin clinical studies following therapy with MabThera. 
Klinični laboratorijski rezultati Skupno je bilo 392 od 3.095 (12,7 %) bolnikov z revmatoidnim artritisom v kliničnih študijah zdravljenja z zdravilom MabThera pozitivnih na ADA.
The incidence of treatment-induced/enhanced anti-rHuPH20 antibodies, only measured in patients in the subcutaneous arm was 12%. 
Incidenca z zdravljenjem povzročenega/okrepljenega nastajanja protiteles proti rHuPH20 (rekombinantni humani hialuronidazi), ki so jo merili le v skupini bolnikov, ki je prejemala podkožno obliko zdravila, je bila 12 %.
None of the patients who tested positive for anti-rHuPH20 antibodies tested positive for neutralizing antibodies. 
Nobeden od bolnikov, ki so bili pozitivni na protitelesa proti rHuPH20, ni bil pozitiven na nevtralizirajoča protitelesa.
In the clinical trial evaluating MabThera maintenance treatment in relapsed/refractory follicular lymphoma, median IgG levels were below the lower limit of normal (LLN) (< 7 g/L) after induction treatment in both the observation and the MabThera groups. 
V kliničnem preskušanju za oceno vzdrževalnega zdravljenja z zdravilom MabThera pri ponovitvi folikularnih limfomov ali neodzivni bolezni je bila mediana koncentracije IgG po indukcijskem zdravljenju pod spodnjo mejo normalne vrednosti (SMN) (< 7 g/L) tako v opazovani skupini kot v skupini z zdravilom MabThera.
Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia. 
Kronična limfocitna levkemija (KLL) je najbolj pogosta oblika levkemije pri odraslih.
In the CLL first-line study, Binet stage C patients experienced more adverse events in the R-FC arm compared to the FC arm (R-FC 83% vs. FC 71%). 
V študiji pri bolnikih s KLL v prvi liniji zdravljenja so imeli bolniki s stopnjo C po Binetu več neželenih dogodkov v skupini R-FC v primerjavi s skupino FC (R-FC 83 % proti FC 71 %).
• heart problems - such as reduced heart rate or chest pain (angina) 
· težave s srcem - na primer upočasnjen srčni utrip ali bolečina v prsih (angina pektoris)
The number of rituximab plus low-dose prednisone patients off prednisone therapy or on minimal therapy (prednisone dose of 10 mg or less per day) compared to standard-dose prednisone patients over the 24-month treatment period shows a steroid-sparing effect of MabThera (Figure 4). 
Število bolnikov z rituksimabom in majhnim odmerkom prednizona (brez prednizonskega zdravljenja ali z minimalnim zdravljenjem (odmerek prednizona 10 mg ali manj na dan)) v primerjavi z bolniki s standardnim odmerkom prednizona v obdobju 24-mesečnega zdravljenja kaže, da zdravilo MabThera zmanjša potrebo po kortikosteroidih (slika 4).
During the treatment course with MabThera subcutaneous formulation, other medicinal products for subcutaneous administration should preferably be given at different sites. 
Med ciklom zdravljenja s podkožno obliko zdravila MabThera je treba druga zdravila za podkožno uporabo po možnosti injicirati na drugih mestih.
MabThera was administered on the first day of the treatment cycle. 
Zdravilo MabThera so prejeli prvi dan cikla zdravljenja.
• blood clotting problems, decrease of red blood cell production and increase of red blood cell destruction (aplastic haemolytic anaemia), swollen or enlarged lymph nodes 
· motnje strjevanja krvi, zmanjšano nastajanje rdečih krvnih celic in povečano propadanje rdečih krvnih celic (aplastična hemolitična anemija), oteklost ali povečanje bezgavk
10 mL vial - Pack of 2 vials 
10-ml viale: škatla z 2 vialama
In patients treated with MabThera, the occurrence of pre-existing ischemic cardiac conditions becoming symptomatic, such as angina pectoris, has been observed, as well as atrial fibrillation and flutter. 
Pri bolnikih, ki so se zdravili z zdravilom MabThera, so opazili simptomatiko že obstoječe ishemične bolezni srca, kot je angina pektoris, ter tudi atrijsko fibrilacijo in undulacijo.
The estimated half-life of Mabthera subcutaneous formulation of 1600 mg is 30 days, the estimated clearance is 0.22 L/day and the volume of distribution of the central compartment is 4.65 L. 
Porazdelitev/izločanje Ocenjeni razpolovni čas podkožne oblike zdravila MabThera 1600 mg je 30 dni, ocenjen očistek kreatinina je 0,22 l/dan in volumen porazdelitve centralnega razdelka 4,65 l. Posebne skupine bolnikov
MabThera 1400 mg is used to treat Non-Hodgkin's lymphoma in adults. 
Zdravilo MabThera 1400 mg se uporablja za zdravljenje ne-Hodgkinovega limfoma pri odraslih.
You will be given MabThera 1600 mg with other medicines called “chemotherapy”. 
Zdravilo MabThera 1600 mg boste dobili skupaj z drugimi zdravili, ki jih imenujemo kemoterapija.
In a trial designed to evaluate the safety of a more rapid MabThera infusion in patients with rheumatoid arthritis, patients with moderate-to-severe active RA who did not experience a serious IRR during or within 24 hours of their first studied infusion were allowed to receive a 2-hour intravenous infusion of MabThera. 
V študiji, osnovani za proučitev varnosti 120-minutne infuzije zdravila MabThera pri bolnikih z revmatoidnim artritisom, so bolniki z zmerno do hudo aktivnim revmatoidnim artritisom, ki niso imeli resne reakcije, povezane z infuzijo, med ali v 24 urah po prvem infundiranju, lahko prejeli 2-urno intravensko infuzijo zdravila MabThera.
Patients received 2 x 1000 mg intravenous infusions of MabThera or placebo in combination with MTX. 
Bolniki so prejeli dve intravenski infuziji po 1000 mg zdravila MabThera ali placeba v kombinaciji z metotreksatom.
Significant difference from placebo at the primary time point: * p < 0.05, **p < 0.001 ***p ≤ 0.0001 
Značilna razlika v primerjavi s placebom ob času primarnega cilja študije: * p < 0,05; **p < 0,001; ***p ≤ 0,0001
• allergic reactions that are most likely to occur during an infusion, but can occur up-to 24-hours after infusion 
· alergijske reakcije, ki se najverjetneje pojavijo med infuzijo, a se lahko pojavijo tudi do 24 ur po infuziji, · dolgotrajna depresija, · izpadanje las.
• you are allergic to rituximab, other proteins which are like rituximab, or any of the other ingredients of this medicine (listed in section 6) 
· ste alergični na rituksimab, druge podobne beljakovine ali katero koli sestavino tega zdravila
No studies on the effects of MabThera on the ability to drive and use machines have been performed, although the pharmacological activity and adverse reactions reported to date suggest that MabThera would have no or negligible influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Študij o vplivu zdravila MabThera na sposobnost za vožnjo in upravljanje strojev niso izvedli, čeprav opisano farmakološko delovanje in neželeni učinki kažejo, da vpliva na to ni ali je le zanemarljiv.
Patients treated with MabThera must be given the patient alert card with each infusion. 
Bolniki, ki prejemajo zdravilo MabThera, morajo ob vsaki infuziji dobiti opozorilno kartico.
This syndrome may be associated with some features of tumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphaetemia, acute renal failure, elevated lactate dehydrogenase (LDH) and may be associated with acute respiratory failure and death. 
Ta sindrom ima lahko nekatere značilnosti sindroma razpada tumorja, npr. hiperurikemijo, hiperkaliemijo, hipokalciemijo, hiperfosfatemijo, akutno ledvično odpoved, zvišano laktat-dehidrogenazo (LDH), ter ga lahko spremlja akutna odpoved dihal in smrt.
In patients with rheumatoid arthritis, granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis in disease remision or pemphigus vulgaris, premedication with 100 mg intravenous methylprednisolone should be completed 30 minutes prior to MabThera infusions to decrease the incidence and severity of infusion related reactions (IRRs). 
Pri bolnikih z revmatoidnim artritisom, granulomatozo s poliangiitisom (Wegenerjevo granulomatozo), mikroskopskim poliangiitisom v remisiji ali navadnim pemfigusom je treba 30 minut pred pričetkom infundiranja zdravila MabThera zaključiti z intravenskim dajanjem 100 mg metilprednizolona za zmanjšanje incidence in resnosti reakcij, povezanih z infuzijo.
In the post-marketing setting five cases of MabThera overdose have been reported. 
Med obdobjem trženja je bilo opisanih pet primerov prevelikega odmerjanja zdravila MabThera.
Depending on the severity of the IRR and the required interventions, temporarily or permanently discontinue MabThera. 
Glede na resnost z infuzijo povezanih reakcij in potrebne ukrepe, je treba zdravilo MabThera ukiniti ali ga začasno prekiniti.
Before starting MabThera subcutaneous injections, all patients must always receive beforehand, a full dose of MabThera by intravenous infusion, using MabThera intravenous formulation (see section 4.4). 
Pred začetkom dajanja zdravila MabThera s podkožnimi injekcijami morajo vsi bolniki predhodno prejeti polni odmerek zdravila MabThera v intravenski infuziji z uporabo intravenske oblike zdravila MabThera (glejte poglavje 4.4).
Gastrointestinal perforation in some cases leading to death has been observed in patients receiving MabThera for treatment of non-Hodgkin lymphoma. 
Perforacijo prebavil, ki je v nekaterih primerih povzročila smrt, so opazili pri bolnikih, ki so prejemali zdravilo MabThera za zdravljenje ne-Hodgkinovega limfoma.
Patients with a high tumour burden or with a high number (≥25 x 109/L) of circulating malignant cells such as patients with CLL, who may be at higher risk of especially severe cytokine release syndrome, should be treated with extreme caution. 
Bolnike z velikim tumorskim bremenom ali velikim številom (≥ 25 x 109/l) malignih celic v krvnem obtoku, kot so bolniki s KLL, ki imajo morda večje tveganje za posebno hud sindrom sproščanja citokinov, je treba zdraviti izjemno pazljivo.
Previously untreated patients with CD20-positive, Follicular Lymphoma Grade 1, 2 or 3a (n=283) were enrolled in the stage 2. 
V 2. stopnjo so bili vključeni predhodno nezdravljeni bolniki s CD20-pozitivnimi folikularnimi limfomi gradusa 1, 2 ali 3a (n = 283).
The risk of acute administration-related reactions associated with the subcutaneous formulation of MabThera was assessed in two open-label trials involving patients with follicular lymphoma during induction and maintenance (SABRINA/BO22334) and during maintenance only (SparkThera/BP22333). 
Tveganje za akutne reakcije, povezane z dajanjem podkožne oblike zdravila MabThera, so ocenili v dveh odprtih preskušanjih, ki sta zajeli bolnike s folikularnimi limfomi med indukcijskim in vzdrževalnim zdravljenjem (SABRINA, BO22334) in samo med vzdrževalnim zdravljenjem (SparkThera, BP22333).
Administration related reactions have been observed in up to 50% of patients treated with MabThera subcutaneous formulation in clinical trials. 
Z dajanjem zdravila povezane reakcije so zabeležili pri do 50 % bolnikov, ki so v kliničnih preskušanjih prejemali podkožno obliko zdravila MabThera.